Product Dossier
RIDAURA
Product Dossier for RIDAURA (auranofin, Amdipharm Mercury). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: Amdipharm Mercury
- Active ingredient: auranofin
- Therapeutic area: Musculoskeletal
- Same area: NAPROSYN
- Same area: PROXEN
What it is Ridaura is an auranofin 3 mg tablet .
Approved indications
The provided sources do not contain information about the approved therapeutic indications for Ridaura.
Dosing overview
The provided sources do not contain information about dosing recommendations for Ridaura.
Key safety warnings
The provided sources do not contain information about key safety warnings for Ridaura.
Contraindications
The provided sources do not contain information about contraindications for Ridaura.
PBS listing
Ridaura is listed on the PBS in two formulations: a 3 mg tablet at an ex-manufacturer price of A$139.37 and a 3 mg capsule at an ex-manufacturer price of A$800.00. Both are restricted listings as of the latest schedule dated 2026-05-01.
Regulatory history
Ridaura auranofin 3 mg tablet was first registered on the ARTG on 14 August 1991. In July 2016, the PBAC recommended a change to add a maximum quantity of 100 to the auranofin 3 mg listing for rheumatoid arthritis, at the same price per tablet and under the same listing conditions.